Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the pharmacokinetics of an investigational 2 mg
sublingual nicotine tablet (Pharmaceutical Productions Inc.) to a 2 mg Commit® nicotine
lozenge (GlaxoSmith Kline) in a randomized crossover design in 6 male and female otherwise
healthy smokers.